Research programme: siRNA hearing loss therapies - Alnylam Pharmaceuticals

Drug Profile

Research programme: siRNA hearing loss therapies - Alnylam Pharmaceuticals

Latest Information Update: 16 May 2014

Price : $50

At a glance

  • Originator Sirna Therapeutics
  • Developer Massachusetts General Hospital
  • Class
  • Mechanism of Action RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Sensorineural hearing loss

Most Recent Events

  • 06 Mar 2014 Alnylam Pharmaceuticals acquires Sirna Therapeutics
  • 30 Dec 2006 Sirna Therapeutics has been acquired by Merck and Co
  • 06 Oct 2005 Preclinical trials in Sensorineural hearing loss in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top